News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biologics, Inc. (NC) Selected by Genentech (RHHBY) as Strategic Partner for Launch of New Targeted Oral Oncology Therapy


9/8/2011 9:53:08 AM

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., an integrated oncology management company, announces today that it has been selected by Genentech, a member of the Roche Group, as the strategic partner to support their suite of services for Zelboraf® (vemurafenib). Zelboraf was approved by the FDA on August 17 as a new oral therapy for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test. In collaboration with Genentech, Biologics is a key provider of patient access, clinical support and pharmacy services for Zelboraf patients.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES